TOOTH REGENERATION MARKET ANALYSIS

Key Developments

• In February 2024, Toregem Biopharma Co., a pharmaceutical startup based in Osaka, revealed its plans to initiate clinical trials shortly for an innovative drug designed to promote the regeneration of teeth in humans. Supported by Kyoto University, the company has demonstrated promising results in animal studies and anticipates a significant advancement in human trials by 2030, offering the prospect of transforming dental healthcare.
• In January 2023, RevBio Inc., a medical device company, obtained approval from the Italian Ministry of Health to initiate a pilot clinical trial involving 15 patients. The trial aims to evaluate the efficacy of Tetranite, the company's adhesive biomaterial, in bone regeneration within the mandibular and maxillary dental arches.
• In October 2022, WuXi Biologics, global Contract Research Development and Manufacturing Organization and Toregem BioPharma, a biopharma company inked a Memorandum of Understanding (MoU) to establish a strategic partnership for the development of TRG035. This regenerative drug targets USAG-1 and is intended for the treatment of congenital adentia, a dental disorder.
• In June 2022, VideaHealth, a provider of dental artificial intelligence (AI) solutions, announced the acquisition of a Medical Device Establishment License (MDEL) from Health Canada for its product, Videa Caries Assist. This AI-powered algorithm specializes in dental caries (cavity) detection. VideaHealth's AI and software solutions empower dentists to enhance their analysis of patient X-rays, streamline reimbursement processes, and offer improved transparency and accuracy in treatment recommendations.